Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:38:08.380Z.
Consensus retrieved: 2026-10-06T14:01:11.432Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:38:08.380Z.
Quote observation: 2026-10-06T16:34:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1ca0602d484fef860d1886a06048f849113dfee726f77a026e2ec96edb2346c6
Forward PE Ratio (N/A) = Dated Quote Price ($1.68) / Consensus Forward EPS ($-0.25)
FORWARD PE RATIO
N/A
MediciNova, Inc.
Market Cap
$82.45M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| MediciNova, Inc. (MNOV) | $82.45M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.58M | N/A |
| Nutriband Inc. (NTRB)vs › | $82.05M | 4.30 |
| Citius Oncology, Inc. (CTOR)vs › | $81.81M | 8.80 |
| LENSAR Inc (LNSR)vs › | $83.21M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $83.24M | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $83.85M | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.10M | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $79.82M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.68, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.26 | $-0.27 – $-0.23 | 3 | n/m |
| 2027-12-31 | $-0.45 | $-0.50 – $-0.39 | 2 | n/m |
| 2028-12-31 | $0.08 | $-0.12 – $0.28 | 2 | 20.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
